Literature DB >> 31156166

A Pilot Study of Changes in Medial Temporal Lobe Fractional Amplitude of Low Frequency Fluctuations after Sildenafil Administration in Patients with Alzheimer's Disease.

Niyatee Samudra1, Michael Motes2,3, Hanzhang Lu4, Min Sheng5, Ramon Diaz-Arrastia6, Michael Devous1,2, John Hart1,2,3, Kyle B Womack1,2,3.   

Abstract

Alzheimer's disease (AD) is the most common cause of neurodegenerative cognitive impairment, defined by abnormal accumulations of amyloid-β and tau. Approaches directly targeting these proteins have not resulted in a disease modifying therapy. Neurovascular unit dysfunction is a feature of AD offering an alternative target for intervention. Sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, improves cognitive functioning in mouse models of AD. Recent work in AD patients has demonstrated increased cerebral blood flow, as well as brain oxygen utilization after a single dose of sildenafil. Its effect on nitric oxide-cGMP signaling may have downstream effects on neuroplasticity, amyloid-β processing, and improved neurovascular unit function. Fractional amplitude of low frequency fluctuations (fALFF) assesses spontaneous neural activity via resting state fMRI BOLD signal (0.01-0.08 or 0.10 Hz). In AD, other assessments have revealed increased fALFF in hippocampi and parahippocampal gyri. Here, we examined the effects of a single dose of sildenafil on fALFF in a cohort of 10 AD patients. We found a decrease (p < 0.03, α= 0.05) in fALFF an hour after sildenafil administration in the right hippocampus. Additionally, cerebral vascular reactivity in response to carbon dioxide inhalation, a measure of neural vascular reserve previously collected on most of these participants, was not significantly correlated with this decrease, implying that change in fALFF may not have been solely due to altered vascular reactivity to CO2. We demonstrate that in patients with AD, hippocampal fALFF decreases in response to sildenafil, suggesting a normalization. These findings support further investigation into the effects of sildenafil in AD.

Entities:  

Keywords:  Alzheimer’s disease; cognitive impairment; fractional amplitude of low zzm321990frequency fluctuations; functional magnetic resonance imaging; sildenafil.

Year:  2019        PMID: 31156166      PMCID: PMC6743329          DOI: 10.3233/JAD-190128

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  34 in total

1.  An improved approach to detection of amplitude of low-frequency fluctuation (ALFF) for resting-state fMRI: fractional ALFF.

Authors:  Qi-Hong Zou; Chao-Zhe Zhu; Yihong Yang; Xi-Nian Zuo; Xiang-Yu Long; Qing-Jiu Cao; Yu-Feng Wang; Yu-Feng Zang
Journal:  J Neurosci Methods       Date:  2008-04-22       Impact factor: 2.390

2.  Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience.

Authors:  Nathan A Johnson; Geon-Ho Jahng; Michael W Weiner; Bruce L Miller; Helena C Chui; William J Jagust; Maria L Gorno-Tempini; Norbert Schuff
Journal:  Radiology       Date:  2005-03       Impact factor: 11.105

3.  Measuring the thickness of the human cerebral cortex from magnetic resonance images.

Authors:  B Fischl; A M Dale
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

4.  Dissociable effects of acetylcholinesterase inhibitors and phosphodiesterase type 5 inhibitors on object recognition memory: acquisition versus consolidation.

Authors:  Jos Prickaerts; Ayhan Sik; Franz Josef van der Staay; Jan de Vente; Arjan Blokland
Journal:  Psychopharmacology (Berl)       Date:  2004-07-24       Impact factor: 4.530

Review 5.  Phosphodiesterase type 5 inhibition improves early memory consolidation of object information.

Authors:  Jos Prickaerts; Ayhan Sik; Wilma C G van Staveren; Guido Koopmans; Harry W M Steinbusch; Franz Josef van der Staay; Jan de Vente; Arjan Blokland
Journal:  Neurochem Int       Date:  2004-11       Impact factor: 3.921

6.  Detection of PCC functional connectivity characteristics in resting-state fMRI in mild Alzheimer's disease.

Authors:  Hong-Ying Zhang; Shi-Jie Wang; Jiong Xing; Bin Liu; Zhan-Long Ma; Ming Yang; Zhi-Jun Zhang; Gao-Jun Teng
Journal:  Behav Brain Res       Date:  2008-08-22       Impact factor: 3.332

7.  The oscillating brain: complex and reliable.

Authors:  Xi-Nian Zuo; Adriana Di Martino; Clare Kelly; Zarrar E Shehzad; Dylan G Gee; Donald F Klein; F Xavier Castellanos; Bharat B Biswal; Michael P Milham
Journal:  Neuroimage       Date:  2009-09-24       Impact factor: 6.556

8.  How does chronic sildenafil prevent vascular oxidative stress in insulin-resistant rats?

Authors:  Alexandra Oudot; Delphine Behr-Roussel; Olivier Le Coz; Sarah Poirier; Jacques Bernabe; Laurent Alexandre; François Giuliano
Journal:  J Sex Med       Date:  2009-10-20       Impact factor: 3.802

9.  Daily treatment with sildenafil reverses endothelial dysfunction and oxidative stress in an animal model of insulin resistance.

Authors:  Delphine Behr-Roussel; Alexandra Oudot; Stéphanie Caisey; Olivier L E Coz; Diane Gorny; Jacques Bernabé; Chris Wayman; Laurent Alexandre; François A Giuliano
Journal:  Eur Urol       Date:  2007-11-20       Impact factor: 20.096

10.  Analysis of the efficacy and safety of sildenafil citrate in the geriatric population.

Authors:  Alexander Müller; Lizette Smith; Marilyn Parker; John P Mulhall
Journal:  BJU Int       Date:  2007-07       Impact factor: 5.588

View more
  5 in total

1.  Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's disease.

Authors:  Jiansong Fang; Pengyue Zhang; Yadi Zhou; Chien-Wei Chiang; Juan Tan; Yuan Hou; Shaun Stauffer; Lang Li; Andrew A Pieper; Jeffrey Cummings; Feixiong Cheng
Journal:  Nat Aging       Date:  2021-12-06

Review 2.  The Interplay between cGMP and Calcium Signaling in Alzheimer's Disease.

Authors:  Aileen Jehle; Olga Garaschuk
Journal:  Int J Mol Sci       Date:  2022-06-24       Impact factor: 6.208

Review 3.  Phosphodiesterase Inhibitors for Alzheimer's Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale.

Authors:  Owen Sanders; Lekshmy Rajagopal
Journal:  J Alzheimers Dis Rep       Date:  2020-06-16

Review 4.  Memory Enhancers for Alzheimer's Dementia: Focus on cGMP.

Authors:  Ernesto Fedele; Roberta Ricciarelli
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-13

Review 5.  Repurposing Licensed Drugs for Use Against Alzheimer's Disease.

Authors:  Leslie C Norins
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.